Such agents may be particularly useful for patients with breast cancer harboring EZH2-mediaed repression of CDKN1C. Furthermore, we show that upregulation of EZH2 and the corresponding downregulation of CDKN1C occur in multiple human cancers. This evidence concerns the gene CDKN1C and breast cancer.